selected scholarly activity
-
conferences
- KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.. Journal of Clinical Oncology. 9513-9513. 2016
- A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma.. Journal of Clinical Oncology. 2015
- 508 A phase Ib trial of AMG386 and temsirolimus in patients with advanced sold tumors (PJC-008/NCI#9041). European Journal of Cancer. 165-166. 2014
- Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM). Journal of Clinical Oncology. 2013
- A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Journal of Clinical Oncology. 2012
- IMPROVED 6-MONTH SURVIVAL RATE IN SUBJECTS WITH PROSTATE STEM CELL ANTIGEN POSITIVE TUMORS IN A GLOBAL, RANDOMIZED PHASE 2 TRIAL COMPARING GEMCITABINE VS. GEMCITABINE + AGS-1C4D4 (ASP6182) IN METASTATIC PANCREATIC CANCER. Annals of Oncology. v12-v12. 2011
- Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology. 2011
- A phase II trial of the Src kinase inhibitor AZD0530 in patients with metastatic or locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A trial of the PMH phase II consortium.. Journal of Clinical Oncology. e14544-e14544. 2010
- Phase II study of vorinostat in patients with advanced melanoma.. Journal of Clinical Oncology. 8530-8530. 2010
- Baseline radiological staging in primary breast cancer: impact of an educational intervention on adherence to published guidelines.. Breast Cancer Research and Treatment. S207-S207. 2005
-
journal articles
- Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use. Current Oncology. 31:425-435. 2024
- An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Surveillance Strategies in Patients with Stage I, II, III or Resectable IV Melanoma Who Were Treated with Curative Intent. Clinical Oncology. 36:243-253. 2024
- Pembrolizumab-induced immune-related sclerosing cholangitis. BMJ Case Reports. 16:e256125-e256125. 2023
- Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review. Journal for ImmunoTherapy of Cancer. 11:e006500-e006500. 2023
- Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition. Current Oncology. 30:4527-4537. 2023
- A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Oncology. 13:3216-3226. 2022
- KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. European Journal of Cancer. 160:1-11. 2022
- Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma. Current Oncology. 27:204-214. 2020
- Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review. Cancer Treatment Reviews. 87:102032-102032. 2020
- Is Access to Care Associated With Stage at Presentation and Survival for Melanoma Patients?. Medical and Surgical Dermatology. 23:586-594. 2019
- Update on Immunotherapeutics in the Management of Metastatic Melanoma.. Skin therapy letter. 24:8-11. 2019
- A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma. Investigational New Drugs. 34:231-235. 2016
- A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041). Investigational New Drugs. 34:104-111. 2016
- Phase II trial of vorinostat in advanced melanoma. Investigational New Drugs. 32:526-534. 2014
- A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Investigational New Drugs. 32:243-249. 2014
- Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Annals of Oncology. 24:1792-1801. 2013
- A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Investigational New Drugs. 30:1158-1163. 2012
- A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Investigational New Drugs. 29:1045-1049. 2011
- Baseline radiological staging in primary breast cancer: impact of educational interventions on adherence to published guidelines. Journal of Evaluation in Clinical Practice. 13:647-650. 2007